Should I buy or sell SOPHiA GENETICS stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SOPHiA GENETICS in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SOPH shares. View SOPH analyst ratings or view top-rated stocks .

What is SOPHiA GENETICS's stock price target for 2024?

2 Wall Street research analysts have issued 12-month price targets for SOPHiA GENETICS's stock. Their SOPH share price targets range from $8.00 to $8.00. On average, they predict the company's share price to reach $8.00 in the next year. This suggests a possible upside of 67.7% from the stock's current price. View analysts price targets for SOPH or view top-rated stocks among Wall Street analysts .

How have SOPH shares performed in 2024?

SOPHiA GENETICS's stock was trading at $4.71 at the beginning of the year. Since then, SOPH shares have increased by 1.3% and is now trading at $4.77. View the best growth stocks for 2024 here .

Are investors shorting SOPHiA GENETICS?

SOPHiA GENETICS saw a increase in short interest in March. As of March 31st, there was short interest totaling 52,600 shares, an increase of 22.3% from the March 15th total of 43,000 shares. Based on an average trading volume of 54,500 shares, the days-to-cover ratio is currently 1.0 days. Currently, 0.1% of the shares of the stock are short sold. View SOPHiA GENETICS's Short Interest .

When is SOPHiA GENETICS's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our SOPH earnings forecast .

How were SOPHiA GENETICS's earnings last quarter?

SOPHiA GENETICS SA (NASDAQ:SOPH) announced its quarterly earnings data on Tuesday, March, 5th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.12. The company had revenue of $17.05 million for the quarter, compared to analysts' expectations of $16.78 million. SOPHiA GENETICS had a negative trailing twelve-month return on equity of 47.40% and a negative net margin of 126.63%. During the same quarter in the prior year, the firm posted ($0.22) EPS.

What guidance has SOPHiA GENETICS issued on next quarter's earnings?

SOPHiA GENETICS updated its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $78.0 million-$81.0 million, compared to the consensus revenue estimate of $82.1 million.

When did SOPHiA GENETICS IPO?

SOPHiA GENETICS (SOPH) raised $234 million in an initial public offering (IPO) on Friday, July 23rd 2021. The company issued 13,000,000 shares at a price of $17.00-$19.00 per share.

How do I buy shares of SOPHiA GENETICS?

Shares of SOPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SOPH

SOPHiA GENETICS (SOPH) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free SOPH Stock Alerts

$4.77

-0.03 (-0.63%)

(As of 11:17 AM ET)

Compare

Today's Range: $4.71
▼
$4.85
50-Day Range: $4.21
▼
$5.62
52-Week Range: $2.13
▼
$7.37

Volume: 8,187 shs
Average Volume: 59,088 shs
Market Capitalization: $311.15 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

Get SOPHiA GENETICS alerts:

SOPHiA GENETICS MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 67.7% Upside
$8.00 Price Target
Short Interest: Healthy
0.11% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.13
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.06) to ($0.91) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.45 out of 5 stars

Medical Sector

701st out of 918 stocks

Biological Products, Except Diagnostic Industry

117th out of 153 stocks

3.5

Analyst's Opinion

Consensus Rating
SOPHiA GENETICS has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
SOPHiA GENETICS has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.11% of the float of SOPHiA GENETICS has been sold short.
Short Interest Ratio / Days to Cover
SOPHiA GENETICS has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in SOPHiA GENETICS has recently increased by 22.33%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
SOPHiA GENETICS does not currently pay a dividend.
Dividend Growth
SOPHiA GENETICS does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SOPH.

1.7

News and Social Media Coverage

News Sentiment
SOPHiA GENETICS has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for SOPHiA GENETICS this week, compared to 2 articles on an average week.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, SOPHiA GENETICS insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.88% of the stock of SOPHiA GENETICS is held by insiders.
Percentage Held by Institutions
Only 31.59% of the stock of SOPHiA GENETICS is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for SOPHiA GENETICS are expected to grow in the coming year, from ($1.06) to ($0.91) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of SOPHiA GENETICS is -3.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of SOPHiA GENETICS is -3.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
SOPHiA GENETICS has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About SOPHiA GENETICS Stock (NASDAQ:SOPH)

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

SOPH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SOPH Stock News Headlines

April 18, 2024 | investing.com

Unilabs adopts SOPHiA GENETICS AI for cancer diagnostics

April 17, 2024 | abcnews.go.com

'Shopaholic' author Sophie Kinsella reveals brain cancer diagnosis

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 15, 2024 | americanbankingnews.com

SOPHiA GENETICS SA (NASDAQ:SOPH) Sees Significant Increase in Short Interest

April 13, 2024 | msn.com

RHOC’s Lauri Peterson Shares Glimpse Into ‘Saddest Day of My Life’ After Son Josh Waring’s Death

April 13, 2024 | msn.com

Leicester girl constantly on sedatives gets 'pacemaker for the brain'

April 9, 2024 | markets.businessinsider.com

RBC Capital Sticks to Its Buy Rating for SOPHiA GENETICS (SOPH)

April 4, 2024 | prnewswire.com

SOPHiA GENETICS and Strand Life Sciences Announce New Strategic Partnership

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 2, 2024 | prnewswire.com

Laboratorio Barnafi-Krause is Live on SOPHiA DDM™

March 28, 2024 | msn.com

Americas dengue outbreak is the ‘worst to date’

March 28, 2024 | msn.com

A promising discovery in a rare neurodegenerative disease

March 28, 2024 | msn.com

Discovering the Hidden Science of Everyday Wonders

March 21, 2024 | msn.com

USask and Sophia Genetics partner to improve ovarian cancer trial

March 15, 2024 | finance.yahoo.com

SOPHiA GENETICS and The French Kidney Cancer Research Network (UroCCR) Publish Results from Multiyear Collaboration

March 14, 2024 | msn.com

The Worms of Chernobyl Have Apparently Conquered Radiation

March 9, 2024 | finance.yahoo.com

SOPHiA GENETICS SA (NASDAQ:SOPH) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

March 7, 2024 | seekingalpha.com

SOPHiA GENETICS SA (SOPH) Q4 2023 Earnings Call Transcript

March 7, 2024 | globenewswire.com

SOPHiA GENETICS to Present at the Barclays 26th Annual Global Healthcare Conference

March 6, 2024 | marketwatch.com

Sophia Genetics Shares Sink After Weak 4Q, Guidance

March 6, 2024 | msn.com

Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

March 6, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: SOPHiA GENETICS (SOPH), Green Thumb Industries (OtherGTBIF) and Marinus (MRNS)

March 6, 2024 | markets.businessinsider.com

Buy Rating Affirmed for SOPHiA GENETICS Amid Growth and Market Expansion Potential

March 6, 2024 | finance.yahoo.com

Q4 2023 Sophia Genetics SA Earnings Call

March 6, 2024 | finance.yahoo.com

SOPHiA GENETICS SA (NASDAQ:SOPH) Q4 2023 Earnings Call Transcript

March 6, 2024 | finance.yahoo.com

SOPHiA GENETICS Full Year 2023 Earnings: EPS Misses Expectations

March 5, 2024 | msn.com

SOPHiA Genetics misses top-line and bottom-line estimates; initiates FY24 outlook

See More Headlines

Receive SOPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SOPHiA GENETICS and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/05/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:SOPH
CUSIP: N/A
CIK: 1840706
Web: www.sophiagenetics.com
Phone: 41-21-694-1060
Fax: N/A
Employees: 430
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.00
High Stock Price Target: $8.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +67.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.22)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-78,980,000.00
Net Margins: -126.63%
Pretax Margin: -125.85%
Return on Equity: -47.40%
Return on Assets: -36.43%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.16
Quick Ratio: 3.97

Sales & Book Value

Annual Sales: $62.37 million
Price / Sales: 4.99
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.16 per share
Price / Book: 1.51

Miscellaneous

Outstanding Shares: 65,230,000
Free Float: 62,048,000
Market Cap: $311.15 million
Optionable: Not Optionable
Beta: 1.17

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. Jurgi Camblong M.B.A. (Age 45)
Ph.D., Co-Founder, CEO & Director
Comp: $1.07M
Mr. Ross Jordan Muken B.Sc. (Age 43)
Executive VP, CFO & COO
Mr. Abhimanyu Verma
Senior VP & CTO
Dr. Zhenyu Xu Ph.D. (Age 41)
Executive VP & Chief Scientific Officer
Katherine Bailon
Vice President of Investor Relations
Mr. Daan van Well L.L.M. (Age 49)
M.B.A., Executive VP, Chief Legal & Compliance Officer
Ms. Manuela Da Silva Valente B.A. (Age 53)
Senior VP & Chief People Officer
Mr. Kevin Puylaert
VP & MD of EMEA
Dr. Philippe Menu M.B.A. (Age 42)
M.D., Ph.D., Executive VP, Chief Medical Officer & Chief Product Officer
Mr. Peter Casasanto
Senior VP & Chief BioPharma Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SOPH Stock Analysis - Frequently Asked Questions

Should I buy or sell SOPHiA GENETICS stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SOPHiA GENETICS in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SOPH shares.
View SOPH analyst ratings or view top-rated stocks.
What is SOPHiA GENETICS's stock price target for 2024?: 2 Wall Street research analysts have issued 12-month price targets for SOPHiA GENETICS's stock. Their SOPH share price targets range from $8.00 to $8.00. On average, they predict the company's share price to reach $8.00 in the next year. This suggests a possible upside of 67.7% from the stock's current price.
View analysts price targets for SOPH or view top-rated stocks among Wall Street analysts.
How have SOPH shares performed in 2024?: SOPHiA GENETICS's stock was trading at $4.71 at the beginning of the year. Since then, SOPH shares have increased by 1.3% and is now trading at $4.77.
View the best growth stocks for 2024 here.
Are investors shorting SOPHiA GENETICS?: SOPHiA GENETICS saw a increase in short interest in March. As of March 31st, there was short interest totaling 52,600 shares, an increase of 22.3% from the March 15th total of 43,000 shares. Based on an average trading volume of 54,500 shares, the days-to-cover ratio is currently 1.0 days. Currently, 0.1% of the shares of the stock are short sold.
View SOPHiA GENETICS's Short Interest.
When is SOPHiA GENETICS's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our SOPH earnings forecast.

How were SOPHiA GENETICS's earnings last quarter?: SOPHiA GENETICS SA (NASDAQ:SOPH) announced its quarterly earnings data on Tuesday, March, 5th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.12. The company had revenue of $17.05 million for the quarter, compared to analysts' expectations of $16.78 million. SOPHiA GENETICS had a negative trailing twelve-month return on equity of 47.40% and a negative net margin of 126.63%. During the same quarter in the prior year, the firm posted ($0.22) EPS.
What guidance has SOPHiA GENETICS issued on next quarter's earnings?: SOPHiA GENETICS updated its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $78.0 million-$81.0 million, compared to the consensus revenue estimate of $82.1 million.
When did SOPHiA GENETICS IPO?: SOPHiA GENETICS (SOPH) raised $234 million in an initial public offering (IPO) on Friday, July 23rd 2021. The company issued 13,000,000 shares at a price of $17.00-$19.00 per share.
How do I buy shares of SOPHiA GENETICS?: Shares of SOPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SOPH) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

SOPHiA GENETICS (SOPH) Stock Price, News & Analysis

SOPHiA GENETICS MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About SOPHiA GENETICS Stock (NASDAQ:SOPH)

SOPH Stock Price History

SOPH Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

SOPH Stock Analysis - Frequently Asked Questions

Overall MarketRank^™